Skip to content

US · ELVN · BIOTECHNOLOGY

Enliven Therapeutics, Inc. (ELVN) intrinsic value and stock valuation

$46.53as of 2026-11-21 · Mkt cap 4.32B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Enliven Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values ELVN with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ELVN’s statements →

Enliven Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Boulder, CO 80301 enliventherapeutics.com

How the business is doing

Fiscal 2017–2025, USD

Revenue
$0.00
20172025
Net income
-$-103.69M
20172025
Free cash flow
-$-70.46M
20172025
Total equity
$459.6M+40.3% 5y CAGRd
20172025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2017–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-119.66M-$-104.55M-$-83.53M-$-38.79M-$-24.76M
Net income-$-103.69M-$-89.02M-$-71.58M-$-37.66M-$-24.74M
EPSd-$-1.83M-$-1.89M-$-2.01M-$-6.03M-$-3.16M
Operating cash flow-$-70.3M-$-73.19M-$-61.27M-$-32.08M-$-19.13M
Capital expenditure-$-160K-$-40K-$-150K-$-610K-$-190K
Free cash flow-$-70.46M-$-73.24M-$-61.42M-$-32.69M-$-19.32M
Total assets$476.2M$325.8M$271.9M$83.3M$113.3M
Total debt$400K$0.00$340K$320K$160K
Net debt-$-98.5M-$-124.12M-$-99.81M-$-75.21M-$-109.86M
Total equity$459.6M$309.9M$245.9M-$-76.83M$106.9M
Cash and short-term investments$462.6M$313.4M$253.2M$75.5M$110M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$260K$0.00$0.00$0.00$0.00
Gross profit-$-260K$0.00$0.00$0.00$0.00
Research and development expenses$85.9M$80.8M$64.6M$31M$20.5M
Selling, general and administrative expenses$33.8M$23.8M$19M$7.77M$4.29M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$119.4M$104.6M$83.5M$38.8M$24.8M
Cost and expenses$119.7M$104.6M$83.5M$38.8M$24.8M
Interest income$16M$14.9M$12M$1.13M$20K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$260K$320K$300K$210K$120K
Ebitda-$-103.43M-$-88.47M-$-71.29M-$-37.45M-$-24.62M
Operating income-$-119.66M-$-104.55M-$-83.53M-$-38.79M-$-24.76M
Total other income/expenses, net$16M$15.8M$12M$1.13M$20K
Income before tax-$-103.69M-$-88.79M-$-71.58M-$-37.66M-$-24.74M
Income tax expense$0.00$230K$0.00$0.00$0.00
Net income-$-103.69M-$-89.02M-$-71.58M-$-37.66M-$-24.74M
Weighted average shares outstanding$56.7M$47.1M$35.6M$6.25M$7.81M
Weighted average diluted shares outstanding$56.7M$47.1M$35.6M$6.25M$7.82M
Balance sheet
20252024202320222021
Cash and short-term investments$462.6M$313.4M$253.2M$75.5M$110M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$474.9M$318.1M$266.2M$77.8M$110.7M
Property, plant and equipment, net$420K$460K$1.06M$1.52M$950K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$50K$0.00
Total non-current assets$1.29M$7.63M$5.72M$5.54M$2.66M
Total assets$476.2M$325.8M$271.9M$83.3M$113.3M
Accounts payable$2.16M$1.34M$530K$3.44M$2.52M
Short-term debt$400K$0.00$340K$320K$160K
Deferred revenue$0.00$0.00$0.00$5.51M$0.00
Total current liabilities$16.6M$15.9M$25.9M$9.71M$5.75M
Long-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$110K$0.00$70K$150.4M$710K
Capital lease obligations$400K$0.00$340K$320K$160K
Total liabilities$16.7M$15.9M$26M$160.1M$6.47M
Common stock$60K$50K$40K$0.00$0.00
Retained earnings-$-347.17M-$-243.47M-$-154.45M-$-82.86M-$-45.2M
Accumulated other comprehensive income (loss)$330K$60K$140K-$-150K$0.00
Total equity$459.6M$309.9M$245.9M-$-76.83M$106.9M
Total investments$363.7M$189.3M$153M$50K$0.00
Total debt$400K$0.00$340K$320K$160K
Net debt-$-98.5M-$-124.12M-$-99.81M-$-75.21M-$-109.86M
Cash flow statement
20252024202320222021
Net income-$-103.69M-$-89.02M-$-71.58M-$-37.66M-$-24.74M
Depreciation and amortization$260K$320K$300K$210K$120K
Stock-based compensation$34M$20.2M$12.9M$3.19M$1.92M
Change in working capital-$-1.12M-$-4.54M$1.4M$440K$3.57M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$820K$810K-$-2.25M$410K$1.73M
Net cash provided by operating activities-$-70.3M-$-73.19M-$-61.27M-$-32.08M-$-19.13M
Investments in property, plant and equipment-$-160K-$-40K-$-150K-$-610K-$-190K
Acquisitions, net$0.00$0.00$0.00$35M$0.00
Net cash used for investing activities-$-173.84M-$-36M-$-148.41M-$-610K-$-190K
Common stock issued$218.9M$39.2M$161.2M-$-1.23M-$-1.02M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$218.9M$133.2M$234.3M-$-1.8M-$-1.02M
Net change in cash-$-25.27M$24M$24.6M-$-34.49M-$-20.34M
Cash at end of period$98.9M$124.2M$100.2M$75.6M$110.1M
Operating cash flow-$-70.3M-$-73.19M-$-61.27M-$-32.08M-$-19.13M
Capital expenditure-$-160K-$-40K-$-150K-$-610K-$-190K
Free cash flow-$-70.46M-$-73.24M-$-61.42M-$-32.69M-$-19.32M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Enliven Therapeutics, Inc.

        Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.

        CEO
        Richard A. Fair
        Employees
        60
        Beta
        0.26

        Explore

        Frequently asked questions

        What is the intrinsic value of Enliven Therapeutics, Inc. (ELVN)?

        InvestorsCraft does not currently publish an intrinsic value for ELVN. How the IC value is calculated.

        Is ELVN undervalued?

        InvestorsCraft does not publish an undervaluation signal for ELVN at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.